Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04554732 · ClinicalTrials.gov registry record · Early Phase 1
Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia
A Early Phase 1 study of Alopecia and Hair Loss, sponsored by University of Arizona.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT04554732 is a Early Phase 1 study of Alopecia and Hair Loss that has completed, run by University of Arizona. The registered enrollment target is 28 participants, below the 123-participant average among 13 other Alopecia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04554732, a Early Phase 1 study of Alopecia and Hair Loss, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary aim is to provide a preliminary assessment of the efficacy of the investigational topical formula, KGF-HS, as a prophylactic treatment for chemotherapy induced alopecia. Hypothesis: KGF-HS will result in less than 50% hair loss by the end of 4 cycles of chemotherapy. The investigators will evaluate hair loss using the CTCAE (Common Terminology Criteria for Adverse Events) v4.0 alopecia grading scale.
Conditions Studied
Interventions
- DRUG Keratinocyte growth factor
Study Locations (1)
Arizona
- University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-04-27 |
| Est. Completion | 2022-06-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04554732
The ClinicalTrials.gov registry entry for NCT04554732 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 13 other Alopecia trials with a reported enrollment target (77% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Keratinocyte growth factor is the first listed.
NCT04554732 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT04554732 about?
NCT04554732 is a clinical study titled "Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia". Primary aim is to provide a preliminary assessment of the efficacy of the investigational topical formula, KGF-HS, as a prophylactic treatment for chemotherapy induced alopecia. Hypothesis: KGF-HS will result in less than 50% hair loss by the end of 4 cycles of chemotherapy. The investigators will ...
What is the current status of trial NCT04554732?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2020-04-27. Estimated completion is 2022-06-24.
What conditions does trial NCT04554732 study?
This clinical trial studies the following conditions: Alopecia, Hair Loss, Chemotherapy-Induced Change, Alopecia Drugs.
What interventions are being tested in trial NCT04554732?
The interventions under investigation include: Keratinocyte growth factor (DRUG).
Who is sponsoring clinical trial NCT04554732?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04554732 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
RECRUITING · NA
-
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
RECRUITING · NA
-
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
RECRUITING · NA
-
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
RECRUITING · NA
-
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.